About RenovoRx
RenovoRx is a company based in Los Altos (United States) founded in 2009. RenovoRx has raised $10.91 million across 7 funding rounds from investors including Boston Scientific, BtoV and Astia. The company has 10 employees as of December 31, 2024. RenovoRx offers products and services including RenovoCath Device and TAMP Therapy Platform. RenovoRx operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Insulet, among others.
- Headquarter Los Altos, United States
- Employees 10 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Renovorx, Inc.
-
Annual Revenue
$43 K (USD)0as on Dec 31, 2024
-
Net Profit
-$8.81 M (USD)13.86as on Dec 31, 2024
-
EBITDA
-$10.97 M (USD)3.74as on Dec 31, 2024
-
Total Equity Funding
$10.91 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Mar 20, 2026
-
Investors
Boston Scientific
& 8 more
-
Employee Count
10
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of RenovoRx
RenovoRx is a publicly listed company on the NASDAQ with ticker symbol RNXT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of RenovoRx
RenovoRx offers a comprehensive portfolio of products and services, including RenovoCath Device and TAMP Therapy Platform.
FDA-cleared device for targeted drug delivery in oncology treatments.
Platform for precise intra-arterial drug administration to minimize side effects.
People of RenovoRx
Unlock access to complete
Unlock access to complete
Funding Insights of RenovoRx
RenovoRx has successfully raised a total of $10.91M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RenovoRx
RenovoRx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, BtoV and Astia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage agnostic VC firm funding companies in Europe
|
Locked | Locked | Locked | |
|
Women-led startups are funded through stage-agnostic investments and angel networks.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused VC firm investing in early stage startups in the US
|
Locked | Locked | Locked |
Investor details for RenovoRx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RenovoRx
Investment portfolio details for RenovoRx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RenovoRx
Detailed financials for RenovoRx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renovorx Comparisons
Peer comparison for RenovoRx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RenovoRx
RenovoRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Insulet, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of RenovoRx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renovorx
Complete news archive for RenovoRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RenovoRx
RenovoRx was founded in 2009 and raised its 1st funding round 4 years after it was founded.
RenovoRx is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
RenovoRx is a funded company, having raised a total of $10.91M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at RenovoRx is 10.
Annual revenue of RenovoRx is $43K as on Dec 31, 2024.
Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
RenovoRx's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
RenovoRx offers RenovoCath Device and TAMP Therapy Platform.
Yes, RenovoRx is publicly traded on NASDAQ under the ticker symbol RNXT.
RenovoRx has 9 investors. Key investors include Boston Scientific, BtoV, Astia, The Angels’ Forum, and The Halo Fund.
The ticker symbol of RenovoRx is RNXT on NASDAQ.